Background: Hemophilia is a group of bleeding disorders resulting from coagulation factor VIII(A), IX(B), or XI(C) deficiency. The bleeding tendancy is different from severe to mild depending on the levels of deficiency. Replacement therapy with exogenous factor or plasma can effectively ameliorate the bleeding complications in hemophilia patients. 

Model: Anti-FVIII/oligonucleotide induce hemophiliaAnti-FVIII antibody or specific antisense induced hemophilia

Standard study duration: 4-8 weeks

Clinical endpoint: Bleeding tests, coagulation tests, factor assays…

Features: Hemostasis, hematology, coagulation factors, potency, tolerability, and safety assessment…

For more information about these models, please contact Mr. James Song, mailto:james.song@prisysbiotech.com